The high prevalence of TMPRSS2-ERG rearrangements (B60%) in prostate cancer (CaP) leads to androgenic induction of the ETS-related gene (ERG ) expression. However, the biological functions of ERG overexpression in CaP remain to be understood. ERG knockdown in TMPRSS2-ERG expressing CaP cells induced striking morphological changes and inhibited cell growth both in cell culture and SCID mice. Evaluation of the transcriptome and specific gene promoters in ERG siRNA-treated cells and investigation of gene expression signatures of human prostate tumors revealed ERG-mediated activation of C-MYC oncogene and the repression of prostate epithelial differentiation genes (PSA and SLC45A3/ Prostein). Taken together, these data combining cell culture and animal models and human prostate tumors reveal that ERG overexpression in prostate tumor cells may contribute to the neoplastic process by activating C-MYC and by abrogating prostate epithelial differentiation as indicated by prostate epithelial specific markers.
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ETS factors including ERG have been implicated in diverse cancers (Seth and Watson, 2005; Turner and Watson, 2008) . As TMPRSS2-ERG fusions represent the majority (>95%) of TMPRSS2-ETS factor alterations described in CaP thus far, this study focuses on tumor biologic functions of ERG overexpression in CaP. EWS-ERG fusions have been described in a small subset of Ewing's sarcoma, whereas ERG overexpression without fusion was highlighted in acute myeloid leukemia and acute T-lymphoblastic leukemia (Marcucci et al., 2005; Baldus et al., 2006) . TMPRSS2-ERG fusion in CaP cells may lead to androgen-dependent overexpression of near full-length ERG-encoded products. Among the nine reported splice variants of ERG, ERG1-3 encode prototypical proteins with ERG3 being the longest (Owczarek et al., 2004) .
Comparison of the wild-type ERG3 and TMPRSS2-ERG3-encoded proteins revealed truncation at the N-terminus of ERG (Figure 1a ) due to the TMPRSS2-ERG fusion A (Tomlins et al., 2005) . Thus, the TMPRSS2-ERG fusion transcripts may encode truncated ERG proteins at the amino terminus. Thus, due to N-terminal alterations of the TMPRSS2-ERG-encoded protein(s) and the complex nature of ERG splice variants, we reasoned that targeting knockdown of the known ERG splice variants, would provide an effective strategy to evaluate the functions of the TMPRSS2 promoter-driven ERG overexpression in CaP. We initially evaluated the effects of ERG knockdown on cell biologic and tumorigenic properties of VCaP cells (Korenchuk et al., 2001 ) that harbor overexpression of TMPRSS2-ERG type A fusion, frequently detected in human prostate tumors (Demichelis and Rubin, 2007; Furusato et al., 2008) . Five ERG siRNAs were screened by assessing the inhibition of ectopically expressed ERG proteins in HEK-293 cells transfected with TMPRSS2-ERG2 or TMPRSS2-ERG3 expression vectors or by assessing the inhibition of ERG in VCaP cells (data not shown). Inhibitory effects of the selected ERG siRNA for further studies and experimental controls are shown in Figures 1b and c and in Supplementary Figure 1 . This ERG siRNA is targeted to a 19 bp region in exon 10 and is predicted to inhibit all known ERG splice variants (Owczarek et al., 2004) . For detecting ERG protein, an anti-ERG peptide antibody was raised against the DFHGIAQALQPHPPESSLYKYPSDLPYMGSYHA HPQKMNFVAPHPPAL polypeptide in our laboratory (Supplementary Methods). ERG expression knockdown in VCaP cells resulted in striking cell morphologic alterations as evidenced by slow growing and clumped cells within 6-8 days (Figure 2a and Supplementary  Figure 2) . Also, there was significant inhibition of the androgen-dependent cell proliferation, S phase of the cell cycle and p-Rb in response to ERG knockdown in VCaP cells (Figures 2b and c) . However, no significant apoptosis was observed. ERG siRNA did not have any effect on LNCaP cells that do not express detectable ERG due to the lack of TMPRSS2-ERG genomic rearrangement in this cell line (data not shown). When ERG siRNA-transfected VCaP cells were injected in SCID mice, striking inhibition of the tumorigenicity was noted (Figure 2d ). Only two of nine mice developed detectable tumors (22%) at day 42. By contrast, five of five (100%) mice in the control group developed large tumors (Figure 2d table) . Taken together, these data provide the first insight into the critical function of ERG in the growth of prostate tumor cells in cell culture and in mice. These data support recent transgenic mice studies showing that the overexpression of ETV1 (Tomlins et al., 2007) or ERG (Klezovitch et al., 2008; Tomlins et al., 2008) in mouse prostate may induce the features of early CaP and also provide important new insights into the therapeutic potential of the ERG knockdown in CaP cells.
To delineate potential biochemical mechanisms of ERG siRNA-mediated cell growth and tumor growth inhibitory effects, ERG siRNA-regulated transcriptome was analyzed in VCaP cells. Cells were treated with 50 nM of either ERG siRNA or nontargeting siRNA (NT) control. The efficiency of ERG inhibition was assessed by monitoring ERG protein levels (Figure 3a , insert). Gene expression changes were evaluated by using Affymetrix HG U133 Plus 2.0 high-density oligonucleotide human genome arrays. Comparison of gene expression profiles between NT and ERG siRNA by using a functional cocitation-based program (BiblioSphere, Genomatix GmbH, Munich, Germany (Scherf et al., 2005) ) highlighted key genes commonly involved in cancer-specific regulatory nodes such as C-MYC, PCNA and p53 (Supplementary Figure 3) . Evaluations of common gene expression alterations between the ERG siRNA-regulated transcriptome in VCaP cells and gene expression alterations associated with ERG overexpressing human prostate tumors from our and others data (Iljin et al., 2006) prompted us to further analyze C-MYC (Figure 3a, Supplementary Figure 4) , one of the major players in cancer pathways. Downregulation of C-MYC by ERG siRNA was confirmed at RNA and protein levels in VCaP cells (Figure 3b) . Furthermore, recruitment of ERG to the C-MYC P2 promoter (Meulia et al., 1992) downstream ETS element (V$ETSF_PDEF ¼ Prostate-derived ETS factor element (Oettgen et al., 2000) ) in VCaP cells was detected by chromatin immunoprecipitation (ChIP) assay. ERG siRNA consistently decreased ERG recruitment to this C-MYC promoter downstream ETS element. These data suggest that ERG expression under androgenic control may lead to the elevated expression of C-MYC in CaP cells.
ERG siRNA-regulated transcriptome in VCaP cells revealed striking upregulation of a number of genes (KLK3/PSA, SLC45A3/prostein, C15ORF, MSMB/ PSP94, SCGB1D2) whose expression are restricted to prostate epithelium, suggesting that ERG interferes with prostate epithelial differentiation ( Supplementary  Figure 3) . While these data are in agreement with similar (Tomlins et al., 2008) , we show direct role of ERG in the modulation of prostate epithelium differentiation markers. Consistent with our GeneChIP data, we observed inverse correlation between C-MYC and PSA expression in response to ERG knockdown in VCaP cells (Figure 3c left panel) . Furthermore, consistent with the ERG siRNA data, adenoviral expression of ERG in TMPRSS2-ERG negative LNCaP cells or in VCaP cells revealed significantly diminished PSA levels (Supplementary Figure 5) . Immunostaining of the ERG siRNA-treated VCaP cells by PSA and cytokeratin 8 and 18 (CK8/18) antibodies confirmed striking alteration of cellular morphology and elevated PSA (Figure 3c , right panel), suggesting for modulation of the prostate epithelial differentiation markers by ERG.
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ChIP assays revealed recruitment of ERG to the PSA enhancer (androgen responsive element (ARE) III) and to the SLC45A3 (prostein) promoter upstream ETS element (V$ETSF_PDEF) (Figure 3c and d) . As both of these genes are regulated by AR and frequent overlap between AREs and ETS-binding sites have been reported (Massie et al., 2007) , we evaluated the ERGdependent recruitment of the AR to the PSA enhancer (AREIII), and SLC45A3 (prostein) ARE elements. In contrast to diminishing ERG binding, increased recruitment of AR was evident in response to ERG knockdown. These data suggest that the modulation of prostate epithelium-associated genes by ERG may involve AR. As the expression response of prostein showed the strongest effect of ERG knockdown in VCaP cells, we further evaluated the levels of prostein in a subset of human prostate tumors that were previously analyzed for the status of TMPRSS2-ERG fusion A transcript (Furusato et al., 2008) . Although, prostein was detected in both benign and malignant epithelial cells showing variable expression in 26 evaluated 
C Sun et al whole-mount radical prostatectomy specimens, there was an inverse correlation between prostein expression and TMPRSS2-ERG fusion transcripts status (Figure 3d ). Of 17 patients with TMPRSS2-ERG fusion, only one patient (5%) showed high expression of prostein. On the other hand, six of nine (54%) patients lacking TMPRSS2-ERG fusion showed high expression of prostein. Interestingly, SLC45A3 promoter was previously identified as a fusion partner of ETV1 gene in a CaP case (Tomlins et al., 2007) .
Figure 3
TMPRSS2-ERG rearrangements in CaP C Sun et al C-MYC may link ERG to a major oncogenic pathway in prostate cancer; therefore, we addressed morphological effects of C-MYC siRNA and ERG siRNA. (Figure 3e ). Intriguing similarity was observed when C-MYC siRNA and ERG siRNA-treated VCaP cells were compared. Indeed, the upregulation of prostate differentiation genes characteristic to ERG inhibition, PSA and SLC45A3/prostein, was noted. We further evaluated quantitative gene expression features of ERG and C-MYC in a cohort of 37 human prostate tumors. The analysis revealed significant correlation between ERG and C-MYC. In contrast, PCA3 that is frequently overexpressed in prostate tumors showed no correlation with C-MYC. These data establish that C-MYC expression is tightly linked to ERG expression in prostate cancer.
On the basis of the data presented, we propose a working model for ERG functions in prostate tumorigenesis (Figure 4) . The tumor biologic functions of ERG are critical in neoplastic process, as evidenced by the dramatic effects of ERG knockdown on cell morphology/differentiation in culture and inhibition of tumor growth in mice. Although, recent studies using immortalized prostate epithelial cell culture models, such as RWPE and PrEC, have shown the effects of ERG on cell invasion (Klezovitch et al., 2008; Tomlins et al., 2008) , VCaP cell used in our study did not exhibit in vitro features of cell invasion. Despite of this observation, VCaP cell model closely resembles prostate tumors that harbor TMPRSS2-ERG fusions and express prostate epithelial markers.
Taken together, elevated ERG, as a result of the TMPRSS2-ERG fusion, modulates the growth of CaP cells by upregulating C-MYC oncogene and by abrogating the differentiation of prostate epithelium. On the basis of these findings we have defined C-MYC as one of the critical targets of ERG in CaP cells. In summary, this report establishes the oncogenic functions of ERG in CaP cells and defines important downstream targets of ERG-mediated prostate tumorigenesis. Our study also suggests that in addition to ERG, C-MYC may also represent a rational therapeutic target in a large subset (>60%) of prostate cancers harboring ERG overexpression. 
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